We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

First Cell-Free NAb Assay with Superior Sensitivity and Precision Analyzes COVID-19 Immune Response

By LabMedica International staff writers
Posted on 26 Aug 2022
Print article
Image: NAB-Sure SARS-CoV-2 Assay quantifies wild type SARS-CoV-2 virus neutralizing antibodies using qPCR workflows (Photo courtesy of Spear Bio)
Image: NAB-Sure SARS-CoV-2 Assay quantifies wild type SARS-CoV-2 virus neutralizing antibodies using qPCR workflows (Photo courtesy of Spear Bio)

Pharmaceutical drug developers and healthcare researchers need innovative tools to understand COVID-19 immune response and validate vaccines and therapeutics critical to managing the pandemic. Neutralizing antibody (NAb) assays are useful for understanding individual and population immunity against SARS-CoV-2. Study of the antibody response to SARS-CoV-2 provides invaluable data for clinical trials and the development of vaccines to fight the spread of the virus. NAb assays are required components of the clinical trials that identify the effectiveness of a new vaccine against a virus or its compatibility with existing drugs and treatment. Now, a new SARS-CoV-2 NAb test allows labs to work with diverse types of biospecimens and sizes of samples, including serum, plasma, and micro-sampling techniques like dried blood spots (DBS), providing consistent laboratory-to-laboratory results even when comparing different sample types.

The NAB-Sure SARS-CoV-2 Neutralizing Antibody Test Kit from Spear Bio (Woburn, MA, USA) that has been developed by former Harvard University scientists based at the Wyss Institute for Biologically Inspired Engineering (Cambridge, MA, USA) provides a surrogate virus neutralization assay with much higher sensitivity than standard ELISA test formats and cell-based approaches. The NAB-Sure SARS-CoV-2 test kit simplifies testing for SARS-CoV-2 NAbs, producing qualitative and quantitative NAb titer measurements using real-time polymerase chain reaction (PCR). The assay has the accuracy of cell-based assays like the plaque-reduction neutralization testing (PRNT), the gold standard for NAb detection, without the safety concerns and long, complicated workflows. What's more is the assay's capability to analyze small volumes of serum or plasma enables new micro-sampling techniques to be leveraged during collection.

The NAB-Sure SARS-CoV-2 Assay provides an inter-laboratory coefficient of variation (CV) of 4.8% even for extremely small test sample sizes such as a DBS from a finger prick. The test results can help researchers validate vaccines and develop predictive models for antibody durability. Automation compatibility combined with industry-leading accuracy for small volumes promotes high throughput and reduces cost at every stage of testing: sample collection, detection, and analysis.

"Conventional cell-based methods for SARS-CoV-2 neutralizing antibody measurement have poor lab-to-lab consistency," said Spear Bio CTO and co-founder, Feng Xuan. "NAB-Sure SARS-CoV-2 Assay is the first cell-free NAb assay with superior sensitivity and precision. This performance combined with simplified workflows is an opportunity to standardize neutralizing antibody measurements, which is essential for the vaccine validation needed at this stage of the pandemic."

Gold Supplier
SARS-CoV-2 Neutralization Antibody Test
UNICELL-2019-nCoV Neutralization Antibody Test
HPLC System
Jasper HPLC System
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)
5-Diff Auto Hematology Analyzer

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: Mindray ToRCH reagents deliver excellent seroconversion sensitivity (Photo courtesy of Mindray)

Mindray Launches High-Sensitivity and High-Specificity ToRCH Panel

Mindray (Shenzhen, China) has launched the ToRCH Panel that provides high-quality assays to meet different clinical needs. Thanks to the improved raw materials, processes, formulas, reaction models, and... Read more


view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more


view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.